logo
Share SHARE
FONT-SIZE Plus   Neg

Shire's DERMAGRAFT Approved In Canada For Treating Diabetic Foot Ulcers

Shire Plc (SHP.L, SHPG) said its lead regenerative medicine product, DERMAGRAFT (human fibroblast-derived dermal substitute) secured regulatory approval from Health Canada as a class IV medical device for the treatment of diabetic foot ulcers (DFUs), a complication of diabetes.

Shire Regenerative Medicine plans to make DERMAGRAFT available in Canada in the first quarter of 2013, and will leverage Shire's current infrastructure and commercial knowledge of the Canadian healthcare system.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Chuck E. Cheese pizza and arcade chain's parent company is planning for an IPO, reported Reuters. The public offering would be probably in the second half of 2017. According to the report, the chain has initiated discussions with banks, however has not yet hired any underwriters. The offering would help the restaurant chain for a valuation of around $1 billion. The Federal Aviation Administration said that SkyPan International Inc. will pay a civil penalty of $200,000 for violating federal regulations by flying remote-controlled aircraft in congested airspace over New York and Chicago. This is the largest civil penalty issued by the FAA against a drone operator. Citigroup Inc. on Wednesday reported a 7 percent increase in profit for the fourth quarter from last year as lower revenues were more than offset by decreases in cost of credit as well as operating expenses. Adjusted earnings for the quarter beat analysts' expectations, while revenues missed their estimates.
comments powered by Disqus
Follow RTT